

## DAFTAR PUSTAKA

- Alberto Forgiarini Junior, L, Alexandre Kretzmann, N, Porawski, M, Simões Dias, A & Anair Possa Marroni, N 2009, *Experimental diabetes mellitus: oxidative stress and changes in lung structure\**,.
- American Diabetes Association (ADA) 2021a, "Introduction: Standards of medical care in diabetesd2021," *Diabetes Care*, vol. 44, pp. S1–S2.
- American Diabetes Association (ADA) 2021b, "2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021," *Diabetes Care*, vol. 44, pp. S15–S33.
- Azuma, K, Ippoushi, K, Nakayama, M, Ito, H, Higashio, H & Terao, J 2000, "Absorption of Chlorogenic Acid and Caffeic Acid in Rats after Oral Administration," *Journal of Agricultural and Food Chemistry*, vol. 48, no. 11, pp. 5496–5500.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI 2018, *Hasil Utama RISKESDAS 2018*,.
- Bagdas, D, Etoz, BC, Gul, Z, Ziyank, S, Inan, S, Turacozen, O, Gul, NY, Topal, A, Cinkilic, N, Tas, S, Ozyigit, MO & Gurun, MS 2015, "In vivo systemic chlorogenic acid therapy under diabetic conditions: Wound healing effects and cytotoxicity/genotoxicity profile," *Food and Chemical Toxicology*, vol. 81, pp. 54–61.
- Ban, CR, Twigg, SM & Twigg, S 2008, *Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers*,.
- Bonita, JS, Mandarano, M, Shuta, D & Vinson, J 2007, "Coffee and cardiovascular disease: In vitro, cellular, animal, and human studies," *Pharmacological Research*, vol. 55, no. 3, pp. 187–198.
- Calles-Escandon, J & Cipolla, M 2001, *Diabetes and Endothelial Dysfunction: A Clinical Perspective*, viewed <<https://academic.oup.com/edrv/article/22/1/36/2423977>>.
- Chawla, A, Chawla, R & Jaggi, S 2016, "Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum?," *Indian journal of endocrinology and metabolism*, vol. 20, no. 4, pp. 546–551.
- Dirks-Naylor, A 2015, "The benefits of coffee on skeletal muscle," *Life sciences*, vol. 143.

- Domitrović, R, Cvijanović, O, Šušnić, V & Katalinić, N 2014, “Renoprotective mechanisms of chlorogenic acid in cisplatin-induced kidney injury,” *Toxicology*, vol. 324, pp. 98–107.
- Ehrlich, SF, Quesenberry, CP, Van Den Eeden, SK, Shan, J & Ferrara, A 2010, “Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer,” *Diabetes Care*, vol. 33, no. 1, pp. 55–60.
- Farah, A & Donangelo, CM 2006, *Phenolic compounds in coffee 1*,.
- Furman, BL 2021, “Streptozotocin-Induced Diabetic Models in Mice and Rats,” *Current Protocols*, vol. 1, no. 4.
- Gonthier, M-P, Verny, M-A, Besson, C, Ré Mé Sy, C & Scalbert, A 2003, *Nutrient Metabolism Chlorogenic Acid Bioavailability Largely Depends on Its Metabolism by the Gut Microflora in Rats 1*, viewed <<https://academic.oup.com/jn/article/133/6/1853/4688142>>.
- Growth, IC, Ofuwe, AF, Kida, K & Thurlbeck, WM 1987, “Experimental Diabetes and the Lung,” , no. C, pp. 3–7.
- Heldin, CH, Vanlandewijck, M & Moustakas, A 2012, “Regulation of EMT by TGFβ in cancer,” *FEBS Letters*, vol. 586, no. 14, pp. 1959–1970.
- Hoff, CR, Perkins, DR & Davidson, JM 1999, “Elastin gene expression is upregulated during pulmonary fibrosis,” *Connective Tissue Research*, vol. 40, no. 2, pp. 145–153.
- Hsia, CCW & Raskin, P 2007, “Lung function changes related to diabetes mellitus,” in *Diabetes Technology and Therapeutics*.
- I., AAE-A, Hamdy, G, Amin, M & Rashad, A 2013, “Pulmonary function changes in diabetic lung,” *Egyptian Journal of Chest Diseases and Tuberculosis*, vol. 62, no. 3, pp. 513–517.
- International Diabetes Federation 2021, “IDF Diabetes Atlas 10th edition,” viewed <<https://diabetesatlas.org/>>.
- Jang, YJ, Son, HJ, Kim, JS, Jung, CH, Ahn, J, Hur, J & Ha, TY 2018, “Coffee consumption promotes skeletal muscle hypertrophy and myoblast differentiation,” *Food and Function*, vol. 9, no. 2, pp. 1102–1111.
- Kalluri, R & Weinberg, RA 2009, “The basics of epithelial-mesenchymal transition,” *Journal of Clinical Investigation*, vol. 119, no. 6, pp. 1420–1428.

- Kolahian, S, Leiss, V & Nürnberg, B 2019, “Diabetic lung disease: fact or fiction?,” *Reviews in Endocrine and Metabolic Disorders*, vol. 20, no. 3, pp. 303–319.
- Lee, K, Lee, JS, Jang, HJ, Kim, SM, Chang, MS, Park, SH, Kim, KS, Bae, J, Park, JW, Lee, B, Choi, HY, Jeong, CH & Bu, Y 2012, “Chlorogenic acid ameliorates brain damage and edema by inhibiting matrix metalloproteinase-2 and 9 in a rat model of focal cerebral ischemia,” *European Journal of Pharmacology*, vol. 689, no. 1–3, pp. 89–95.
- Lipson, KE, Wong, C, Teng, Y & Spong, S 2012, “CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis,” *Fibrogenesis & Tissue Repair*, vol. 5, no. S1, pp. 2–9.
- Mekala, KC & Bertoni, AG 2019, “Epidemiology of diabetes mellitus,” in *Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas: Volume 1*, Elsevier, pp. 49–58.
- Mobasser, M, Shirmohammadi, M, Amiri, T, Nafiseh, V, Fard, HH & Ghofazadeh, M 2020, “Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis,” *Health Promotion Perspectives*, vol. 10, no. 2, pp. 98–115.
- Ong, KW, Hsu, A & Tan, BKH 2013, “Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation,” *Biochemical Pharmacology*, vol. 85, no. 9, pp. 1341–1351.
- Pitocco, D, Fuso, L, Conte, EG, Zaccardi, F, Condoluci, C, Scavone, G, Incalzi, RA & Ghirlanda, G 2012, “DIABETIC STUDIES The Diabetic Lung-A New Target Organ?,” p. 23.
- Ponticos, M, Holmes, AM, Shi-wen, X, Leoni, P, Khan, K, Rajkumar, VS, Hoyles, RK, Bou-Gharios, G, Black, CM, Denton, CP, Abraham, DJ, Leask, A & Lindahl, GE 2009, “Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen,” *Arthritis and Rheumatism*, vol. 60, no. 7, pp. 2142–2155.
- Qin, L, Zang, M, Xu, Y, Zhao, R, Wang, Y, Mi, Y & Mei, Y 2021, “Chlorogenic Acid Alleviates Hyperglycemia-Induced Cardiac Fibrosis through Activation of the NO/cGMP/PKG Pathway in Cardiac Fibroblasts,” *Molecular Nutrition and Food Research*, vol. 65, no. 2.
- Rajasurya, V, Gunasekaran, K & Surani, S 2020, “Interstitial lung disease and diabetes,” *World Journal of Diabetes*, vol. 11, no. 8, pp. 351–357.

- Satti, NK & Dutt, P 2011, *Amelioration of inflammatory responses by Chlorogenic acid via suppression of pro-inflammatory mediators*, viewed <<https://www.researchgate.net/publication/215730384>>.
- Schuyler, MR, Niewoehner, DE, Inkley, SR & Kohn, R 1976, "Abnormal lung elasticity in juvenile diabetes mellitus," *American Review of Respiratory Disease*, vol. 113, no. 1.
- Sengupta, P 2013, "The Laboratory Rat: Relating Its Age With Human's," *International journal of preventive medicine*, vol. 4, no. 6, pp. 624–630.
- Shi, H, Dong, L, Bai, Y, Zhao, J, Zhang, Y & Zhang, L 2009, "Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats," *European Journal of Pharmacology*, vol. 623, no. 1–3, pp. 119–124.
- Shi, H, Dong, L, Jiang, J, Zhao, J, Zhao, G, Dang, X, Lu, X & Jia, M 2013, "Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway," *Toxicology*, vol. 303, pp. 107–114.
- da Silva Almeida, R, Carvalho de Melo, R, Silvane Sanches Chaves, M, Magno Baptista, G, Silva Margotto, S & Jesuino de Oliveira Andrade, L 2016, *DIABETIC PNEUMOPATHY*.
- Sotler, R, Poljšak, B, Dahmane, R, Jukić, T, Pavan Jukić, D, Rotim, C, Trebše, P & Starc, A 2019, "Prooxidant Activities of Antioxidants and Their Impact on Health," *Acta clinica Croatica*, vol. 58, no. 4, pp. 726–736.
- Talakatta, G, Sarikhani, M, Muhamed, J, Dhanya, K, Somashekar, BS, Mahesh, PA, Sundaresan, N & Ravindra, P v. 2018, "Diabetes induces fibrotic changes in the lung through the activation of TGF- $\beta$  signaling pathways," *Scientific Reports*, vol. 8, no. 1.
- Tian, C ju & Zhen, Z 2019, "Reactive Carbonyl Species: Diabetic Complication in the Heart and Lungs," *Trends in Endocrinology and Metabolism*, vol. 30, no. 8, pp. 546–556.
- Tiwari, P 2015, "Recent trends in therapeutic approaches for diabetes management: A comprehensive update," *Journal of Diabetes Research*, vol. 2015.
- Vracko, R, Thorning, D & Huang, TW 1979, "Basal lamina of alveolar epithelium and capillaries: Quantitative changes with aging and in diabetes mellitus," *American Review of Respiratory Disease*, vol. 120, no. 5, pp. 973–983.
- Wang, YC, Dong, J, Nie, J, Zhu, JX, Wang, H, Chen, Q, Chen, JY, Xia, JM & Shuai, W 2017, "Amelioration of bleomycin-induced pulmonary fibrosis by

chlorogenic acid through endoplasmic reticulum stress inhibition,” *Apoptosis*, vol. 22, no. 9, pp. 1147–1156.

Wheatley, CM, Baldi, JC, Cassuto, NA, Foxx-Lupo, WT & Snyder, EM 2011, “Glycemic control influences lung membrane diffusion and oxygen saturation in exercise-trained subjects with type 1 diabetes: Alveolar-capillary membrane conductance in type 1 diabetes,” *European Journal of Applied Physiology*, vol. 111, no. 3, pp. 567–578.

Wuyts, WA, Agostini, C, Antoniou, KM, Bouros, D, Chambers, RC, Cottin, V, Egan, JJ, Lambrecht, BN, Lories, R, Parfrey, H, Prasse, A, Robalo-Cordeiro, C, Verbeken, E, Verschakelen, JA, Wells, AU & Verleden, GM 2013, “The pathogenesis of pulmonary fibrosis: A moving target,” *European Respiratory Journal*, vol. 41, no. 5, pp. 1207–1218.

Xu, J, Lamouille, S & Derynck, R 2009, “TGF- $\beta$ -induced epithelial to mesenchymal transition,” *Cell Research*, vol. 19, no. 2, pp. 156–172.

Yan, Y, Zhou, X, Guo, K, Zhou, F & Yang, H 2020, “Use of Chlorogenic Acid against Diabetes Mellitus and Its Complications,” *Journal of Immunology Research*, vol. 2020.

Yang, J, Xue, Q, Miao, L & Cai, L 2011, “Pulmonary fibrosis: a possible diabetic complication,” *Diabetes/Metabolism Research and Reviews*, vol. 27, pp. 311–317.

Yue, X, Shan, B & Lasky, JA 2010, “TGF- $\beta$ : Titan of Lung Fibrogenesis,” *Current enzyme inhibition*, vol. 6, no. 2.

Yunus, J, Salman, M, Bamba Ratih Lintin, G, Muchtar, M, Cahyani Ratna Sari, D, Arfian, N & Mansyur Romi, M *Chlorogenic acid attenuates kidney fibrosis via antifibrotic action of BMP-7 and HGF*,.

Zhang, H-Y, Gharaee-Kermani, M, Zhang, K, Karmioli, S & Phan, SH 1996, *Lung Fibroblast  $\alpha$ -Smooth Muscle Actin Expression and Contractile Phenotype in Bleomycin-Induced Pulmonary Fibrosis*,.